Highly effective new anticancer drug shows few side effects in animal studies
A new drug known as OTS964 can eliminate eradicate aggressive human lung cancers that were transplanted into mice, according to recent research.
A new drug known as OTS964 can eliminate eradicate aggressive human lung cancers that were transplanted into mice, according to recent research.
By screening a library of US FDA-approved anticancer drugs that previously wouldn’t have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.
Persons with glioblastoma who undergo repeated resections can have improved survival, indicate the findings of a recent study.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Combining trastuzumab and lapatinib with an anti-VEGFR2 antibody dramatically improved survival in HER2 breast cancer with brain metastases.